Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 882-888

  Park, James H ^a   McMillan, Donald C ^a   Powell, Arfon G ^a,b   Richards, Colin H ^a   Horgan, Paul G ^a   Edwards, Joanne ^a   Roxburgh, Campbell S D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; COLORECTAL CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ADULT; COLORECTAL TUMOR; INFLAMMATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MICROENVIRONMENT;

EID: 84923129730     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1686     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Fleming ID American Joint Committee on Cancer. American Cancer Society. American College of Surgeons. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
3. Horgan PG, McMillan DC. Surgeons and selection of adjuvant therapy for node-negative colonic cancer. Br J Surg 2010; 97: 1459-60.
4. Petersen VCV, Baxter KJK, Love SBS, Shepherd NAN Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51: 65-9.
5. Roxburgh CS, McMillan DC, Richards CH, Atwan M, Anderson JH, Harvey T, et al. The clinical utility of the combination of T stage and venous invasion to predict survival in patients undergoing surgery for colorectal cancer. Ann Surg 2014; 259: 1156-65.
6. Roxburgh CSD, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012; 38: 451-66.
7. Freeman MR, Li Q, Chung LW. Canstroma reaction predict cancer lethality? Clin Cancer Res 2013; 19: 4905-7.
8. Spratt JS Jr, Spjut HJ. Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer 1967; 20: 1976-85.
9. Vayrynen JP, Tuomisto A, Klintrup K, Makela J, Karttunen TJ, Makinen MJ. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer 2013; 109: 1839-47.
10. Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 2014; 110: 1595-605.
11. Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer 2014; 50: 309-19.
12. Park JH, Roxburgh CSD, McMillan DC. Comment on 'Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis.' Br J Cancer 2014; 111: 2372.
13. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-47.
14. Koshida Y, Kuranami M, Watanabe M. Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor. J Surg Res 2006; 134: 270-7.
15. Moserle L, Casanovas O. Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J Intern Med 2013; 273: 128-37.
16. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006; 66: 632-7.
17. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol 2014; 25: 644-51.
18. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 2007; 29: 387-98.
19. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013; 24: 179-85.
20. Roxburgh CS, Richards CH, Macdonald AI, Powell AG, McGlynn LM, McMillan DC, et al. Theinsitu local immune response, tumour senescence and proliferation in colorectal cancer. Br J Cancer 2013; 109: 2207-16.
21. Klintrup K, Mäkinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41: 2645-54.
22. Roxburgh C, Salmond J, Horgan P, Oien K, McMillan D. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009; 45: 2138-45.
23. Petty RD, Samuel LM, Murray GI, MacDonald G, O'Kelly T, Loudon M, et al. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer 2009; 9: 434.
24. Forrest R, Guthrie GJ, Orange C, Horgan PG, McMillan DC, Roxburgh CS. Comparison of visual and automated assessment of tumour inflammatory infiltrates in patients with colorectal cancer. Eur J Cancer 2014; 50: 544-52.
25. Angell HK, Gray N, Womack C, Pritchard DI, Wilkinson RW, Cumberbatch M. Digital pattern recognition-based image analysis quantifies immune infiltrates in distinct tissue regions of colorectal cancer and identifies a metastatic phenotype. Br J Cancer 2013; 109: 1618-24.
26. Mansouri D, McMillan DC, Crighton EM, Horgan PG. Screening for colorectal cancer: what is the impact on the determinants of outcome? Crit Rev Oncol Hematol 2013; 85: 342-9.
27. Church D, Midgley R, Kerr D. Biomarkers in early-stage colorectal cancer: ready for prime time? Dig Dis 2012; 30 Suppl 2: 27-33.